BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Heart
,
Biofuel
,
Clofibrate
,
rs2230926
,
NEUROG3
,
Fatty acid metabolic process
,
Ischemia
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
ol 2
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
No genes found
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
No biogroups found
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
Drug Matrix In Vivo Toxicogenomic Study - Rat Kidney [Codelink]
Broad Connectivity Map (CMAP 2.0) compound database
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
Refinement and complete solution NMR analysis of the structure of a 6-branched 1,3-β-D-glucan (OL-2)…
Screening of CRISPR/Cas9 gRNA for mimicking Powdery Mildew resistant MLO ol-2 mutant.
Synthesis of daldinol and nodulisporin A by oxidative dimerization of 8-methoxynaphthalen-1-ol.
Tomato defense to Oidium neolycopersici: dominant Ol genes confer isolate-dependent resistance via a…
Antioxidant activities of extracts and metabolites isolated from the fungus Antrodia cinnamomea.
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
A Phase 2, Multicenter Open-Label Extension (OLE) Study With ABT-122 in Active Psoriatic Arthritis S…
Metabotypes in the Urinary Excretion of Flavan-3-ol Metabolites: "Metanols"
The Influence of the Microbiome on the Pharmacokinetics of Flavan-3-ols
Surgical Hand Antisepsis With Propan-ol-1 60% Per Rubbing and Scrubbing
Open Label Extension (OLE) of the TDF2 Study, Botswana
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ